Baxter Int'l Receives FDA Approval For Phoxillum Renal Replacement Solutions

(RTTNews) - Baxter International Inc. (BAX) said that Food and Drug Administration or FDA has approved PHOXILLUM Renal Replacement Solutions as replacement solutions in continuous renal replacement therapy or CRRT to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances.

The company said that FDA has granted PHOXILLUM orphan drug designation for use in CRRT.

Hypophosphatemia (abnormally low concentration of phosphate in the blood) is a common electrolyte disturbance in patients treated with CRRT.

PHOXILLUM is the only FDA approved pre-mixed solution containing phosphate in a 5L bag and it is designed to facilitate electrolyte management during CRRT by allowing use of a single type of solution across a wide clinical spectrum of acute kidney injury or AKI patients, Baxter stated.

Baxter anticipates PHOXILLUM phosphate-containing solutions will be available in the United States in the second quarter of 2015.